Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad4-HIV Vaccines with AIDSVAX B/E Boost
NCT02771730Phase 1Terminated
- Sponsor
- Emergent BioSolutions
- Start
- Mar 2015
- Primary completion
- Feb 2017
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ad4-mgag and Ad4-EnvC150 in human immunodeficiency virus infection (HIV) (5 arms), sponsored by Emergent BioSolutions. Primary endpoint: Safety of Ad4-mgag and Ad4-EnvC150 vaccines at 14 months. Started Mar 2015; status: terminated.
02
Drugs
Ad4-mgagAd4-EnvC150
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02771730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771730.